BBIO logo

BridgeBio Pharma (BBIO) Company Overview

Profile

Full Name:

BridgeBio Pharma, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

June 27, 2019

Indexes:

Not included

Website:

http://bridgebio.com

Description:

BridgeBio Pharma, Inc. is a pharmaceutical company engaged in research and development of various drugs for genetic diseases. The company was founded in 2015, with its headquarters located in Palo Alto, California. BridgeBio Pharma's portfolio includes about 20 development programs for various products at different stages of development. The company's main candidates are: BBP-265, an oral low-molecular-weight transthyretin (TTR) intended for the treatment of transthyretin amyloidosis. Infigratinib, an oral selective FGFR1-3 tyrosine kinase inhibitor for the treatment of FGFR-driven cancer and achondroplasia. BBP-631, a preclinical gene transfer candidate product for the treatment of congenital adrenal hyperplasia (CAH) caused by 21OHD. BBP-454, a preclinical research program focused on new approaches to inhibiting KRAS for cancer treatment.

Key Details

Price

$33.22

Market Cap

$6.32 B(Mid cap)

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

$221.90 M(+2285.27% YoY)

Annual EPS

-$2.88(+27.09% YoY)

PE Ratio

-

Annual ROE

36.50%

Annual Debt To Equity

-1.17

Beta

1.26

Events Calendar

Earnings

Next earnings date:

May 2, 2025

Recent quarterly earnings:

Feb 20, 2025

Recent annual earnings:

Feb 20, 2025
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Feb 21, 25 Scotiabank
Sector Outperform
Feb 21, 25 Citigroup
Buy
Feb 21, 25 Cantor Fitzgerald
Overweight
Feb 13, 25 HC Wainwright & Co.
Buy
Feb 12, 25 Scotiabank
Sector Outperform
Dec 23, 24 Evercore ISI Group
Outperform
Dec 16, 24 HC Wainwright & Co.
Buy
Nov 25, 24 Scotiabank
Sector Outperform
Nov 25, 24 HC Wainwright & Co.
Buy
Nov 25, 24 B of A Securities
Buy

Screeners with BBIO included

Growing Shares Outstanding
Mid cap stocks
US stocks
Stocks with high beta
Most recommended stocks
Best performing stocks last 3 months
Stocks below analysts price target
Healthcare sector
All stocks
Biotechnology industry

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Current Price

$33.22
BBIO price is $33.22

Price All-time High

$72.35
BBIO price is currently -54.08% below its historical high of $72.35

Price Analysts Target

$49.50
BBIO price is currently -32.89% lower than the consensus analysts' forecast

Price Most Recent Change

+0.12%
BBIO price was up +0.12% on Mar 5, 2025

Price YTD Change

+21.55%
BBIO price is up +21.55% since January 1st

Price 3-Year Change

+342.34%
BBIO price is up +342.34% over the past 3 years

Market cap

Market Cap

$6.32 B
BBIO market capitalization is $6.32 billion

Market Cap 3-Year Change

+469.95%
BBIO market capitalization is up +469.95% over the past 3 years

Market Cap All-time High

$10.77 B
BBIO market capitalization is currently -41.32% below its historical high of $10.77 billion

Market Cap Sector Rank

90.04%
BBIO market capitalization is higher than 90.04% of companies in Healthcare sector

Technical

Beta

1.26
BBIO beta is 1.26

200-day SMA

$27.85
BBIO price is currently +19.30% above its 200-day simple moving average

14-day RSI

48.88
BBIO 14-day relative strength index is 48.88

30-day Relative Volume

0.96
BBIO 30-day relative volume is 0.96

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Annual Revenue

$221.90 M
BBIO annual revenue is $221.90 million

Annual Revenue Analysts Estimate

$216.69 M
BBIO annual revenue is currently +2.41% higher than the consensus analysts' forecast

Annual Revenue 1-Year Change

+2285.27%
BBIO annual revenue is up +2285.27% year-on-year

Annual Revenue Sector Rank

66.59%
BBIO annual revenue is higher than 66.59% of companies in Healthcare sector

Profit

Annual Gross Profit

$218.02 M
BBIO annual gross profit is $218.02 million

Annual Gross Margin

98.25%
BBIO annual gross profit margin is 98.25%

Annual Operating Profit

-$577.37 M
BBIO annual operating income is -$577.37 million

Annual Operating Margin

-260.19%
BBIO annual operating profit margin is -260.19%

Annual Net Income

-$535.76 M
BBIO annual net profit is -$535.76 million

Annual Net Margin

-241.44%
BBIO annual net profit margin is -241.44%

EPS

Annual EPS

-$2.88
BBIO annual earnings per share is -$2.88

Annual EPS Analysts Estimate

-$3.74
BBIO annual earnings per share is currently -22.96% lower than the consensus analysts' forecast

Annual EPS 1-Year Change

+27.09%
BBIO annual earnings per share is up +27.09% year-on-year

Annual EPS Sector Rank

33.93%
BBIO annual earnings per share is higher than 33.93% of companies in Healthcare sector

ROA & ROE

Annual ROA

-73.11%
BBIO annual return on assets is -73.11%

Annual ROE

36.50%
BBIO annual return on equity is 36.50%

EBIT & EBITDA

Annual EBIT

-$442.90 M
BBIO annual earnings before interest & taxes is -$442.90 million

Annual EBITDA

-$436.83 M
BBIO annual EBITDA is -$436.83 million

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE Ratio

-
BBIO price to earnings ratio value is unknown

PE Ratio Sector Rank

-
BBIO price to earnings ratio is unknown

PB Ratio

PB Ratio

-4.30
BBIO price to book ratio is -4.30

PB Ratio Sector Rank

4.21%
BBIO price to book ratio is higher than 4.21% of companies in Healthcare sector

PS Ratio

PS Ratio

28.47
BBIO price to sales ratio is 28.47

PS Ratio Sector Rank

88.83%
BBIO price to sales ratio is higher than 88.83% of companies in Healthcare sector

Enterprise value

Enterprise Value

$7.37 B
BBIO enterprise value is $7.37 billion

Enterprise Value Sector Rank

90.23%
BBIO enterprise value is higher than 90.23% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-16.87
BBIO EV/EBITDA is -16.87

EV/EBITDA Sector Rank

7.77%
BBIO EV/EBITDA is higher than 7.77% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Annual Current Ratio

4.67
BBIO annual current ratio is 4.67

Annual Quick Ratio

-
BBIO annual quick ratio value is unknown

Leverage

Annual Debt To Equity

-1.17
BBIO annual debt to equity ratio is -1.17

Annual Interest Coverage Ratio

-4.46
BBIO annual interest coverage ratio is -4.46

Risk & Stability

Piotroski F-Score

4
BBIO piotroski f-score is 4

Altman Z-Score

-3.73
BBIO altman z-score is -3.73

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Annual Total Assets

$919.34 M
BBIO annual total assets is $919.34 million

Annual Non Current Assets

$198.65 M
BBIO annual long term assets is $198.65 million

Annual Current Assets

$720.69 M
BBIO annual total current assets is $720.69 million

Annual Cash & Cash Equivalents

$681.10 M
BBIO annual cash & cash equivalents is $681.10 million

Equity

Annual Book Value

-$1.47 B
BBIO annual book value is -$1.47 billion

Annual Working Capital

$566.29 M
BBIO annual working capital is $566.29 million

Liabilities

Annual Total Liabilities

$2.38 B
BBIO annual total liabilities is $2.38 billion

Annual Total Long Term Liabilities

$2.22 B
BBIO annual total long term liabilities is $2.22 billion

Annual Current Liabilities

$154.40 M
BBIO annual total current liabilities is $154.40 million

Annual Accounts Payable

$9.62 M
BBIO annual accounts payable is $9.62 million

Debt

Annual Total Debt

$1.73 B
BBIO annual total debt is $1.73 billion

Annual Total Debt 1-Year Change

-0.53%
BBIO annual total debt is down -0.53% year-on-year

Annual Long Term Debt

$1.73 B
BBIO annual long term debt is $1.73 billion

Annual Short Term Debt

$4.51 M
BBIO annual short term debt is $4.51 million

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Total Expenses

$799.27 M
BBIO annual total expenses is $799.27 million

Annual Operating Expenses

$795.39 M
BBIO annual total operating expenses is $795.39 million

Annual Cost Of Goods Sold

$3.88 M
BBIO annual cost of goods sold is $3.88 million

Annual SGA

$288.93 M
BBIO annual SGA is $288.93 million

Annual D&A

$6.08 M
BBIO annual depreciation & amortization is $6.08 million

Annual Interest Expense

$99.29 M
BBIO annual interest expense is $99.29 million

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Annual CFO

-$520.73 M
BBIO annual cash flow from operations is -$520.73 million

Annual CFO 1-Year Change

+1.33%
BBIO annual cash flow from operations is up +1.33% year-on-year

Annual CFI

$60.78 M
BBIO annual cash flow from investing activities is $60.78 million

Annual CFI 1-Year Change

+12.49%
BBIO annual cash flow from investing activities is up +12.49% year-on-year

Annual CFF

$748.46 M
BBIO annual cash flow from financing activities is $748.46 million

Annual CFF 1-Year Change

+65.76%
BBIO annual cash flow from financing activities is up +65.76% year-on-year

Free CashFlow

Annual FCF

-$529.63 M
BBIO annual free cash flow is -$529.63 million

Annual FCF 1-Year Change

-0.11%
BBIO annual free cash flow is down -0.11% year-on-year

CAPEX

Annual CAPEX

$8.91 M
BBIO annual capital expenditures is $8.91 million

Annual CAPEX 1-Year Change

+582.08%
BBIO annual capital expenditures is up +582.08% year-on-year

Institutional Ownership

Similar stocks

CORT logo
Corcept Therapeutics Incorporated (CORT)
GKOS logo
Glaukos (GKOS)
LEGN logo
Legend Biotech (LEGN)
AXSM logo
Axsome Therapeutics (AXSM)
TFX logo
Teleflex Incorporated (TFX)
MMSI logo
Merit Medical Systems (MMSI)
BPMC logo
Blueprint Medicines (BPMC)
ALKS logo
Alkermes (ALKS)
LNTH logo
Lantheus Holdings (LNTH)

FAQ

  • What is the ticker symbol for BridgeBio Pharma?
  • Does BridgeBio Pharma pay dividends?
  • What sector is BridgeBio Pharma in?
  • What industry is BridgeBio Pharma in?
  • What country is BridgeBio Pharma based in?
  • When did BridgeBio Pharma go public?
  • Is BridgeBio Pharma in the S&P 500?
  • Is BridgeBio Pharma in the NASDAQ 100?
  • Is BridgeBio Pharma in the Dow Jones?
  • When was BridgeBio Pharma's last earnings report?
  • When does BridgeBio Pharma report earnings?
  • Should I buy BridgeBio Pharma stock now?

What is the ticker symbol for BridgeBio Pharma?

The ticker symbol for BridgeBio Pharma is NASDAQ:BBIO

Does BridgeBio Pharma pay dividends?

No, BridgeBio Pharma does not pay dividends

What sector is BridgeBio Pharma in?

BridgeBio Pharma is in the Healthcare sector

What industry is BridgeBio Pharma in?

BridgeBio Pharma is in the Biotechnology industry

What country is BridgeBio Pharma based in?

BridgeBio Pharma is headquartered in United States

When did BridgeBio Pharma go public?

BridgeBio Pharma's initial public offering (IPO) was on June 27, 2019

Is BridgeBio Pharma in the S&P 500?

No, BridgeBio Pharma is not included in the S&P 500 index

Is BridgeBio Pharma in the NASDAQ 100?

No, BridgeBio Pharma is not included in the NASDAQ 100 index

Is BridgeBio Pharma in the Dow Jones?

No, BridgeBio Pharma is not included in the Dow Jones index

When was BridgeBio Pharma's last earnings report?

BridgeBio Pharma's most recent earnings report was on Feb 20, 2025

When does BridgeBio Pharma report earnings?

The next expected earnings date for BridgeBio Pharma is May 2, 2025

Should I buy BridgeBio Pharma stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions